Secunderabad Chronicle

Sepsis Market is Forecast to Witness Remarkable Growth Opportunities at a During the Study Period [2018-2030], States DelveInsight

 Breaking News
  • No posts were found

Sepsis Market is Forecast to Witness Remarkable Growth Opportunities at a During the Study Period [2018-2030], States DelveInsight

June 29
22:24 2021
Sepsis Market is Forecast to Witness Remarkable Growth Opportunities at a During the Study Period [2018-2030], States DelveInsight

Sepsis is the body’s overwhelming and life-threatening response to infection that can lead to tissue damage, organ failure, and death.

DelveInsight’s ‘Sepsis Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Sepsis, historical and forecasted epidemiology as well as the Sepsis market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

 

Some of the imperative takeaways from the Sepsis Market Research Report 

  • According to DelveInsight’s estimates, the highest Sepsis market size was in the US, followed by Japan. 
  • The market size of Antimicrobials, Pressor Agents, and Other Immunomodulatory Agents in 7MM was USD 593.3 million, USD 879.2 million, and USD 229.7 million in 2020, respectively.
  • Several key pharmaceutical companies such as La Jolla Pharmaceuticals, Par Pharmaceutical, Ono Pharmaceutical, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi, Asahi Kasei Pharma Corp, AM-Pharma, ABIONYX Pharma, Revimmune, Baxter Healthcare Corporation, BioMarck Pharmaceuticals, and others are developing novel products to drift the Sepsis treatment scenario positively. 
  • Giapreza (angiotensin II), a drug by La Jolla Pharmaceutical Company, got FDA approval in 2017 as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shocks.
  • The commonly used antibiotics include ceftriaxone (off-label), meropenem (Merrem), ceftazidime (Fortaz), cefotaxime (Claforan), cefepime (Maxipime), piperacillin and tazobactam (Zosyn), ampicillin and sulbactam (Unasyn), imipenem/cilastatin (Primaxin), levofloxacin (Levaquin), and clindamycin (Cleocin). Oritavancin, dalbavancin, and tedizolid are among the antibiotics that the FDA has approved.
  • The increase in awareness among patients/health care providers and the rise in Sepsis incidence worldwide surge the treatment options. Medications with better safety and effectiveness, low cost, and less time-consuming therapies are required in the Sepsis market. There has been an increase in Sepsis clinical trials activity for emerging therapies that will boost the market. 
  • However, a few impediments to Sepsis market growth, such as the lack of pathophysiology comprehension and clinical relevance, may delay diagnosis. Available pharmacological therapies have associated limitations. The increased disease burden is associated with the high cost of treatment. Strict pricing and reimbursement policies, availability of antibiotics, and off-label therapies are other reasons to hinder the market’s growth. 

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/sepsis-market

 

The Sepsis Market Report provides historical as well as forecasted epidemiological analysis segmented into: 

  • Total Incident Cases of Sepsis 
  • Gender-Specific Sepsis Incident Cases 
  • Severity-Specific Incident Cases of Sepsis
  • Origin-Specific Sepsis Incident Cases 

 

Sepsis Emerging Therapies Along with Key Players

  • VBI-S: Vivacelle Bio 
  • Nangibotide (LR12): Inotrem 
  • Allocetra: Enlivex Therapeutics 
  • Adrecizumab: Adrenomed
  • Fetroja/Fetcroja (Cefiderocol): Shionogi
  • Recomodulin (ART-123): Asahi Kasei Pharma Corp.
  • Recombinant human alkaline phosphatase: AM-Pharma
  • CER-001: ABIONYX Pharma
  • CYT107: Revimmune
  • Esmolol (esmolol hydrochloride): Baxter Healthcare Corporation
  • BIO-11006: BioMarck Pharmaceuticals 
  • And several others.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/sepsis-market

 

Table of Contents 

1

Sepsis Key Insights

2

Sepsis Report Introduction

3

Executive Summary of Sepsis 

4

Sepsis Disease Background and Overview 

5

Sepsis Epidemiology and Patient Population

5.1

The United States

5.2

EU5 Countries

5.2.1

Germany

5.2.2

France

5.2.3

Italy

5.2.4

Spain

5.2.5

The United Kingdom

5.3

Japan

6

Sepsis Patient Journey

7

Organisations contributing towards Sepsis

8

Sepsis Marketed Therapies

8.1

Giapreza: La Jolla Pharmaceuticals

8.2

Vasostrict: Par Pharmaceutical

8.3

Onoact Injection (Landiolol hydrochloride): Ono Pharmaceutical

9

Sepsis Emerging Therapies 

9.1

VBI-S: Vivacelle Bio

9.2

Nangibotide (LR12): Inotrem

9.3

Allocetra: Enlivex Therapeutics

9.4

Adrecizumab: Adrenomed

9.5

Fetroja/Fetcroja (Cefiderocol): Shionogi

9.6

Recomodulin (ART-123): Asahi Kasei Pharma Corp.

9.7

Recombinant human alkaline phosphatase: AM-Pharma

9.8

CER-001: ABIONYX Pharma

9.9

CYT107: Revimmune

9.10

Esmolol (esmolol hydrochloride): Baxter Healthcare Corporation

9.11

BIO-11006: BioMarck Pharmaceuticals

10

7MM Sepsis Market Analysis

10.1

The United States Sepsis Market Size

10.2

EU-5 Sepsis Market Size

10.2.1

Germany Market Size

10.2.2

France Market Size

10.2.3

Italy Market Size

10.2.4

Spain Market Size

10.2.5

United Kingdom Market Size

10.3

Japan Sepsis Market Size

11

KOL Views

12

Sepsis Market Drivers

13

Sepsis Market Barriers

14

SWOT Analysis of Sepsis

15

Sepsis Unmet Needs

16

Reimbursement and Sepsis Market Access 

17

Appendix

18

DelveInsight Capabilities

19

Disclaimer

20

About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Services with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.  Also, browse through the deep insights into changing scenario of Pharmaceutical and Biotech arena with the latest news and blog posts.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/sepsis-market

Related Articles